NASDAQ:MNOV MediciNova Q1 2025 Earnings Results & Report $1.31 +0.04 (+3.15%) Closing price 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MediciNova beat analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.06 versus the -$0.14 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call8:00 AM ET MediciNova EPS ResultsActual EPS-$0.06Consensus EPS -$0.14Beat/MissBeat by +$0.08One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersMediciNova Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MediciNova Q1 2025 Earnings FAQ Did MediciNova beat earnings estimates for Q1 2025? MediciNova (NASDAQ:MNOV) reported earnings of -$0.06 per share for Q1 2025, beating the consensus estimate of -$0.14. The report was announced on Tuesday, May 13, 2025. MediciNova Earnings HeadlinesMediciNova FY2026 Earnings Forecast Boosted by HC WainwrightNovember 20 at 1:42 AM | americanbankingnews.comMedicinova IncNovember 14, 2026 | money.usnews.comThis is likely to EXPLODEDr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.November 20 at 1:00 AM | Weiss Ratings (Ad)MediciNova to Participate in the Maxim Growth SummitOctober 6, 2026 | globenewswire.comMediciNova stock tumbles on mixed Phase 2 NAFLD trial dataSeptember 28, 2026 | finance.yahoo.comMediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary EndpointsSeptember 28, 2026 | finance.yahoo.comSee More MediciNova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email. Email Address About MediciNovaMediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines. MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.View MediciNova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.